Top Markets
#1 TENDIES TENDIES +43.22%
#2 GEKKO GEKKO +43.17%
#3 Pons Pons +40.37%
#4 ADO Protocol ADO Protocol +38.68%
#5 Helium Helium +28.36%
#6 Prom Prom +24.56%
#7 龙虾 (Lobster) 龙虾 (Lobster) +20.59%
#8 o1.exchange o1.exchange +17.90%
#9 Main Street Yield Main Street Yield +17.48%
#10 Nillion Nillion +17.32%
Coin of the day
TENDIES TENDIES
Settings
Language
ENGLISH
Currency
USD
Theme
Jiangsu Yahong Meditech Co Ltd Jiangsu Yahong Meditech Co Ltd

Jiangsu Yahong Meditech Co Ltd

688176
Rank in Stocks #9583
Established in 2010 and headquartered in Shanghai, China, Jiangsu Yahong... Established in 2010 and headquartered in Shanghai, China, Jiangsu Yahong Meditech Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutic drugs. Its primary focus lies in medicines targeting genitourinary system cancers, though its pipeline extends to a variety of other diseases, serving both domestic Chinese and international markets. The company's clinical-stage pipeline features several key candidates. Notably, two compounds, APL-1202 (an anti-tumor drug) and APL-1706 (an agent drug), are both undergoing Phase III trials for the treatment of non-muscle invasive bladder cancer. Another promising candidate, APL-1501, an oral MetAP inhibitor, is currently in Phase I testing for addressing urinary system tumors and drug-resistant urinary tract infections. Furthermore, APL-1702, a photodynamic therapy product, is in Phase III for tackling cervical high-grade squamous intraepithelial lesions that arise from HPV infections. Beyond these clinical programs, Jiangsu Yahong Meditech is actively exploring targeted protein degraders in its preclinical phase. This includes ASN-1764, aimed at triple-negative breast cancer; ASN-1780, intended for metastatic castration-resistant prostate cancer; and APL-1901, designed to treat ER-positive breast cancer. The company's developmental efforts also encompass APL-1401, targeting moderately to severely active ulcerative colitis, and ASN-1733, for combating Acinetobacter baumannii infection.
Share Price
$1.72
Last synced: 2026-08-28
Market Cap
$985.07M
Change (1 day)
-0.50%
Change (1 year)
6.01%
Country
CN
Trade Jiangsu Yahong Meditech Co Ltd (688176)

Category

Healthcare
Revenue for Jiangsu Yahong Meditech Co Ltd (688176)
Revenue in Aug 2026 TTM: 0
According to Jiangsu Yahong Meditech Co Ltd latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Jiangsu Yahong Meditech Co Ltd from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 - -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 - -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 - -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 - -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 $6.61B -
IN